Trials / Not Yet Recruiting
Not Yet RecruitingNCT06837389
Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
1. Primary objectives of study:To valuate the tolerability and safety of JY306 in patients with relapsed or refractory CD70 + malignant hematological tumors. 2. Secondary objectives of study:To conduct a preliminary Evaluation of the Efficacy, Pharmacokinetics, and Pharmacodynamics of JY306 in Patients with Relapsed or Refractory CD70+ Malignant Hematological Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | JY306 universal NK cell injection | "3+3" dose escalation trial |
Timeline
- Start date
- 2025-02-15
- Primary completion
- 2026-03-01
- Completion
- 2027-03-01
- First posted
- 2025-02-20
- Last updated
- 2025-02-20
Source: ClinicalTrials.gov record NCT06837389. Inclusion in this directory is not an endorsement.